Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 8/20 | 0.81 |
| ▸ | MAPT | P10636 | 6/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.81 |
| ▸ | HTR1A | P08908 | 1/20 | 0.70 |
| ▸ | HTR2A | P28223 | 1/20 | 0.70 |
| ▸ | HTR7 | P34969 | 1/20 | 0.70 |
| ▸ | HTR6 | P50406 | 1/20 | 0.70 |
| ▸ | GRM5 | P41594 | 3/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | KDM1A | O60341 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8241489 | 0.94 | TP53 (0.74) | TP53MAPTSMN1; SMN2HTR1AHTR2A | |
| SCHEMBL8238113 | 0.87 | TP53 (0.67) | TP53MAPTSMN1; SMN2HTR1AHTR2A | |
| SCHEMBL8241567 | 0.87 | TP53 (0.74) | TP53MAPTSMN1; SMN2HTR1AHTR2A | |
| SCHEMBL8241490 | 0.85 | MAPT (0.62) | TP53MAPTSMN1; SMN2HTR1AHTR2A | |
| SCHEMBL8238827 | 0.85 | TP53 (0.67) | TP53MAPTSMN1; SMN2HTR1AHTR2A | |
| SCHEMBL8238721 | 0.82 | HTR1A (0.80) | TP53MAPTSMN1; SMN2HTR1AHTR2A | |
| SCHEMBL13676929 | 0.82 | HTR1A (0.63) | TP53MAPTSMN1; SMN2HTR1AHTR2A | |
| SCHEMBL3831705 | 0.81 | GRM5 (1.00) | TP53MAPTSMN1; SMN2HTR1AHTR2A | |
| SCHEMBL1346311 | 0.80 | GRM5 (0.70) | TP53MAPTSMN1; SMN2HTR1AHTR2A | |
| SCHEMBL1346789 | 0.79 | GRM5 (0.63) | TP53MAPTSMN1; SMN2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270371-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT. (HU) | 2009-10-29 | — | — | US | disclosed |
| US-20090270371-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT. (HU) | 2009-10-29 | — | — | US | disclosed |
| EP-1962849-B1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT (HU) | 2009-09-30 | — | — | EP | disclosed |
| WO-2007072093-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT. (HU) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270371-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | GRM5, GRIK5, GRM1 | TP53 4885/4885MAPT 1932/4885SMN1; SMN2 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.